Cytokines are intercellular mediators which regulate survival, differentiation and effector functions of cells and has been proven to be related to cancer. Some of them have definite activity, but the understanding of its interaction with the genesis and tumor progression may contribute to the success of preventive and therapeutic protocols. The IL-25 is known for its role in the immune response and it is known that the interaction with its receptor IL-25R induces apoptosis. Little is known about this interaction, only that there is competition for the site of action with IL-17B in neoplastic cells, contributing to tumor progression in these cells. It has been proposed that melatonin may protect normal cells from apoptosis, and conversely, induce it in neoplastic cells. The objective of this study is to control tumor growth through increased apoptosis as a therapeutic strategy in breast neoplasms. Treatment will be performed with IL-25 with or without melatonin and the silencing of IL-17B and human cell lines and primary cultures of canine mammary neoplasms of different grades of malignancy of dogs, with emphasis on inflammatory carcinomas. These results could allow the use of interleukins associated or not with melatonin as therapeutic agents in breast cancer.
News published in Agência FAPESP Newsletter about the scholarship: